Skip to content

High-Intensity focused ultrasound mediated inferior perirenal fat modification therapy for primary hypertension: a pilot safety and efficacy study

High-Intensity focused ultrasound mediated inferior perirenal fat modification therapy for primary hypertension: a pilot safety and efficacy study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024820
Enrollment
Unknown
Registered
2019-07-29
Start date
2017-05-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Blood pressure controlled group:Peri-renal fat modification
Blood pressure uncontrolled group:Peri-renal fat modification

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20-80 years old; 2. The minimun peri-renal fat volume of 8000mm3 is necessary of either side; 3. Patients provided written informed consent to participate in the trial; 4. Patients must meet one of blood pressure criteria of specific group below: (1) Blood pressure unctrolled group(BPU):? An office systolic blood pressure(OSBP) of between 150 mm Hg and 180 mm Hg and a diastolic blood pressure(ODBP) of 90 mm Hg or higher;? A mean 24 h ambulatory systolic blood pressure(AMBP) of between 135 mm Hg and 170 mm Hg.? Prescribed of not more than three antihypertensive drugs with stable doses for at least 6 weeks; (2) Blood pressure controlled group(BPC): An OSBP of between 120 and 140 mm Hg with an ODBP of between 70 and 90 mm Hg; ASBP was controlled less than 130 mmHg; More than one antihypertensive drugs of stable doses prescribed for at least 6 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients with a secondary factor of hypertension; 2. Patients underwent other device based anti-hypertension therapy; 3. Patietns with other severe diseases(eg. end stage renal disease).

Design outcomes

Primary

MeasureTime frame
Office blood pressure;24h mean ambulatory blood pressure;Anti-hypertensive medicaitions;Blood chemistry;Angiotensin II;Blood aldosterone;

Secondary

MeasureTime frame
Office heart rate;24h mean heart rate;Echocardiography;Renal and renal artery ultrasound;abdominal CT scan;

Countries

China

Contacts

Public ContactXiangqing Kong

The First Affiliated Hospital of Nanjing Medical University

kongxq@njmu.edu.cn+86 13951610265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026